Since anti-TNF therapy has not been translated to patients with decompensated cirrhosis due to the high risk of bacterial infection, future work will also determine whether alternative strategies to modulate oxidative stress or the post-transcriptional regulation of DDAH1 in environments of oxidative stress are of benefit in treating portal hypertension. This evidence concerns the gene DDAH1 and portal hypertension.